Manager, Quality Systems & Administration
Tonix Pharmaceuticals Holding Corp - North Dartmouth, MA
Posted Apr 13, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified last checked Jun 13, 2026
- Salary
- $110K-$145K not verified - source not recorded; timestamp not recorded
- 401(k) match
- Listed Source: EMPLR_CONTRIB_INCOME_AMT. source Last checked Jun 13, 2026.
Was this benefit information wrong? Tell us.
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Manager, Quality Systems & Administration North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview: The Manager, Quality Systems
Read the full description at job-boards.greenhouse.io. FewerJobs shows a source-linked preview and links to the original posting.
Apply link not verified; last-live date unavailable.
What verified means
Verified means a displayed claim has a recorded source field, a source URL when available, and a timestamp showing when FewerJobs checked or enriched the evidence.
Related jobs
-
Configuration Manager - Policies and Procedures
Northrop Grumman - United States-Maryland-Linthicum
-
Senior Benefits Lead
Goodyear TIRE & Rubber - US OH Akron Corp Hdqtrs
-
Manager Programs 2
Northrop Grumman - United States-Maryland-Annapolis Junction
-
Senior Claims Examiner - MSI
Baldwin Insurance Group INC Class - Remote US